ArticleFrontiers in immunology2025
Dysregulated arginine metabolism is associated with pro-tumor neutrophil polarization in liver cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neutrophil-based immunotherapy: A metabolic lens on mechanisms and therapeutic implications.Clinical and translational medicine · 2026Review
- Deciphering HPV-Associated Immune Evasion in Cervical Cancer Through Multi-Omics Profiling and Computational Screening.Analytical cellular pathology (Amsterdam) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver hepatocellular carcinoma (LIHC) is a leading cause of cancer-related mortality, with an immunosuppressive tumor microenvironment (TME) contributing to therapeutic resistance. Although neutrophils are recognized as key regulators of LIHC progression, their functional heterogeneity and metabolic drivers are not yet fully understood. Methods: We integrated bulk RNA sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database (GSE39791) alongside scRNA-seq data from GSE149614 and GSE290925. Neutrophils were annotated based on specific marker genes (FCGR3B, CSF3R) and classified into three metabolic states: high arginine state (HAS), intermediate arginine state (DTAS), and low arginine state (LAS) using arginine metabolism-related gene sets. Differentiation trajectories were reconstructed via CytoTRACE and monocle2. Intercellular communication was analyzed using CellChat, while machine learning, incorporating seven different algorithms, was applied to identify key regulatory genes. Results: scRNA-seq analysis revealed three distinct neutrophil subgroups: high (HAS), intermediate (DTAS), and low (LAS) arginine metabolism states. The proportion of LAS neutrophils was significantly enriched in tumor tissues compared to normal tissues (p < 0.001). Trajectory analysis indicated that LAS neutrophils exhibited a less differentiated state. From this landscape, ATP11B and PADI4 were identified as key genes, with PADI4 expression being approximately 3-fold higher in HAS compared to LAS neutrophils. Functional studies demonstrated that silencing PADI4 in LIHC cell lines inhibited cell proliferation by approximately 50% at 96 hours, increased apoptosis by 2-fold, and reduced cell invasion by 50%. Conclusions: Arginine metabolism shapes neutrophil polarization in the LIHC TME. Targeting metabolic pathways may provide new therapeutic strategies to modulate the immune landscape and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.